This opportunity funds milestone-driven, biphasic R61/R33 awards to accelerate precision probiotic interventions. The R61 phase supports identification of unique host biological patterns linked to probiotic response heterogeneity using observational or secondary data. The R33 phase supports mechanistic studies in animal models or humans to validate these patterns and improve probiotic clinical outcomes. The combined award duration is up to 5 years with transition milestones required for phase progression.
Eligible applicants include a wide range of U.S. entities such as county and state governments, tribal organizations, nonprofits, private higher education institutions, and small businesses. Specific eligibility details are provided in the full announcement.
